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ABSTRACT  
Background. There is uncertainty around the optimal surveillance of head and neck cancer patients following 
primary curative treatment. This study aims at assessing the cost-effectiveness of a post-treatment program of 
frequent radiological assessments (maximal approach) compared to a symptom-driven surveillance (minimal 
approach). 
Materials and Methods. A decision-analytic Markov model is developed to assess the cost-utility of two alternative 
follow-up programs with a lifetime horizon. The two interventions differ in the number of radiological assessments 
(i.e. magnetic resonance imaging, computed tomography, and positron emission tomography) performed over a 5-
year period. Clinical and utility parameters are derived from published and unpublished literature and expert 
opinion. The cost analysis is conducted from the perspective of a major Italian region’s healthcare system. Cost-
effectiveness results are expressed as incremental cost per life year gained (LYG) and per quality-adjusted life 
year (QALY) and checked against a cost-effectiveness threshold of €25,000-40,000 per QALY. One-way, two-
way, and probabilistic sensitivity analyses are carried out.  
Results: In the base-case analysis, an intensive program of radiological investigations leads to 0.10 additional 
QALYs (0.15 LYG) and an increase in costs of €1,903 per patient compared to a minimal option, resulting in an 
incremental cost of €19,951/QALY gained (€13,123/LYG). In probabilistic sensitivity analysis, 72% of the results 
lie below the €40,000 threshold (55% below €25,000). 
Conclusions: An intensive post-treatment follow-up with scheduled radiological assessments over time might be 
cost-effective compared to symptom-driven surveillance in head and neck cancer patients. Further research is 
needed to check these results in empirical studies or real-world settings. 
Keywords: head and neck cancer; follow-up; radiological assessments; Markov model; cost-utility analysis. 
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1. Introduction 
Head and neck cancer (HNC) is the sixth most common cancer worldwide; in Europe alone, around 
143,000 people are diagnosed and more than 68,000 die each year because of the disease [1]. The 
incidence in Italy is about 16 cases per 100,000 [2]. Despite the routine introduction of combined-
modality treatment, the 5-year overall survival rate is 40% to 60% [2-4] and up to 50% of patients relapse 
with loco-regional or metastatic recurrences [4-6]; additionally, a constant rate of 2-3% per year of 
second primaries is observed [7].  
A few patients with loco-regional recurrences or second primaries can be salvaged by a potentially 
curative treatment (i.e. surgery or re-irradiation) [1, 4], while most are only suitable for palliative 
treatment usually including a combination of chemotherapeutics and anti-epidermal growth factor 
receptor drugs [8]. The prognosis for patients with recurrent or metastatic disease not eligible for curative 
treatment is very poor, with a median overall survival of around 10 months under the standard scheme 
of platinum-based chemotherapy plus cetuximab [9].  
A post-treatment follow-up program is essential in the first few years after primary treatment to identify 
potentially curable relapses, as well as monitoring long-term therapy-related side effects. However, there 
is no consensus in the medical community around the optimal strategy. Published recommendations are 
mostly based on retrospective studies and expert opinions, whilst the added value of intensive 
radiological assessment over a scheme based on self-reported symptoms (e.g. pain, dysphagia, 
hoarseness) has not yet been confirmed in any prospective study.  
This study evaluates the cost-effectiveness of an intensive follow-up strategy (maximal approach) versus 
a symptom-driven surveillance (minimal approach) using a modeling framework. 
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2. Materials and methods 
A decision-analytic Markov model is developed to assess the long-term health and economic 
consequences of two different surveillance schemes. A randomized controlled trial (HETeCo, 
clinicaltrials.gov identifier NCT02262221) is currently being conducted in Italy and Switzerland to 
compare an intensive versus a non-intensive follow-up program of equal length (i.e. 5 years). The trial 
started in 2014 and is expected to be completed by 2020; thus, it is mainly used to generate a research 
question, while most of the data are obtained from other sources.  
2.1 HETeCo trial 
The full trial protocol is available at clinicaltrials.gov. Briefly, patients with a diagnosis of clinical or 
pathological stage III-IV squamous HNC in the oral cavity, oropharynx, larynx, or hypopharynx and 
without evidence of disease six months after having received radiotherapy with curative intent (alone or 
with systemic therapy or in postoperative setting) are randomly allocated to one of two follow-up 
programs.  
The non-intensive follow-up (arm A, minimal approach), designed according to National Comprehensive 
Cancer Network (NCCN) guidelines [10], comprises several outpatient visits during which patients 
receive both physical and fiber optic endoscopic examinations; laboratory tests are performed once a 
year. Radiological assessment through magnetic resonance imaging (MRI) or computed tomography 
(CT) is performed within six months of completion of treatment and then only at the occurrence of new 
signs or symptoms. Patients are contacted by phone between visits to monitor any health changes and 
instructed how to recognize them. 
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The alternative strategy (arm B) is a more intensive follow-up (maximal approach) where outpatient 
visits and laboratory tests are performed similarly to arm A. Imaging tests are scheduled for all patients 
twice a year in the first two years and annually in the third and fourth years; MRI is preferred over CT 
for all sub-sites except for laryngeal cancer. Positron emission tomography (PET) scans are performed 
annually in the first three years in high-risk patients.  
2.2 Model structure 
The Markov state-transition model (Figure 1) simulates the experience of a hypothetical cohort of 1,000 
patients after being treated for primary stage III-IV HNC; mean age and gender ratio are representative 
of the patients enrolled in the trial (until May 2016). All patients enter the model free of disease and 
move through the different health states according to a set of transition probabilities. Recurrent patients 
are divided based on the intent of the treatment received (i.e. potentially curative or palliative); patients 
treated with curative intent are assigned to either ‘surgery’ or ‘re-irradiation’ states. Patients without 
progression remain in the ‘no evidence of disease’ states; the final, absorbing state is ‘death’.  
The cycle length of the model is one month with a lifetime horizon. Utility weights ranging from 0 (death) 
to 1 (perfect health) and costs are applied to the time spent in each health state. The model is run until 
the whole cohort (i.e. >99%) dies to estimate differences in life years gained (LYG), quality-adjusted life 
years (QALYs) and long-term costs associated with the two follow-up schemes under investigation in 
the HETeCo trial.  
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2.3 Clinical and utility parameters 
Transition probabilities between states are mainly derived from a combination of clinical parameters 
(Tables 1-2). The proportion of potentially salvageable recurrences in the study arm A (25%) is derived 
from the literature [11], while the percentage in group B (50%) is a clinical assumption of the study, 
which is intended to test whether a more intensive radiological assessment could detect a higher rate of 
salvageable relapses. The ‘potentially curative treatment’ state is assumed temporary, meaning that each 
patient can only remain in it for one cycle; surgery is considered the only potentially curative treatment 
for second primaries. The risk of relapsing after secondary treatment is estimated at 3% monthly, based 
on published studies [12-14]; this parameter is also consistent with the 0.009 weekly (i.e. 0.034 monthly) 
adopted by a previous cost-effectiveness model in Italy [15]. Any recurrence (or second primary) beyond 
the first is assumed to be treated with palliative intent only. Patients receiving palliative chemotherapy 
are assumed to have a median survival of 10 months, corresponding to a 1-year overall survival of around 
43% (i.e. 6.6% monthly mortality) [9, 16]. In each health state patients also experience a general risk of 
dying for reasons other than HNC; mortality rates for 5-year age groups are obtained from official 
statistics [17]. Annual probability values reported in the literature are transformed into monthly 
probabilities using the formula: p= 1-exp(-r*t) where p is probability, r is rate and t is the time expressed 
in months [18]. 
The utility parameters are summarized in Table 3. An average utility value for the ‘no evidence of 
disease’ state (i.e. at recruitment) is calculated from the EuroQol 5 Dimensions 5 Levels (EQ-5D-5L) 
trial data using the English tariff set. The same value (i.e. 0.85) is confirmed by a cross-sectional study 
recruiting a comparable population [19]. Utility values for all other states are identified by a systematic 
literature review [20].  
7 
 
 
2.4 Cost data 
The cost analysis is conducted from the perspective of a major Italian region (i.e. Lombardy) healthcare 
system. Unit costs for hospital admissions, specialist visits, radiological exams, laboratory tests and 
outpatient treatment regimens are from diagnosis-related groups (DRGs) and other regional tariffs (year 
2016) (Table 4). The cost of each follow-up program (A or B) performed in the ‘no evidence of disease’ 
state is calculated for 5 years (i.e. standard length of follow-up) and reported in Table 5, according to the 
description provided in the trial protocol. Patients surviving the ‘potentially curative treatment’ states are 
assumed to be monitored within a program resembling the less intensive scheme (arm A). Re-irradiation 
is assumed to involve a cycle of intensity modulated radiation therapy (IMRT) sessions based on current 
practice. Standard platinum-based chemotherapy supplemented with 5-fluoraouracil (5FU) and 
cetuximab until one month before death is assumed for the ‘palliatively treated recurrence’ state; 
additionally, an average cost of dying for HNC is assigned to each patient entering this state based on 
the estimated consumption of formal end-of-life care (i.e. home-based assistance and hospital care). A 
synthesis of monthly cost values for all health states is reported in Table 6. 
2.5 Cost-effectiveness analysis 
Health outcomes (i.e. LYG, QALYs gained) and total costs are combined into an incremental cost-
effectiveness ratio (ICER= 
𝐶𝑜𝑠𝑡 𝐵−𝐶𝑜𝑠𝑡𝐴
LYsB−LYsA
) and cost-utility ratio (ICUR = 
𝐶𝑜𝑠𝑡 𝐵−𝐶𝑜𝑠𝑡𝐴
QALYsB−QALYsA
) to represent 
the incremental cost of achieving one unit of health outcome when an intensive follow-up strategy (arm 
B) replaces a less intensive one (arm A). The ICUR obtained is compared with the range of €25,000-
€40,000 recommended by the Italian Health Economics Association [21]. All costs and outcomes are 
discounted at 3% (converted to 0.247% monthly) and expressed in Euro (€) 2016.  
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2.6 Sensitivity analyses 
One-way sensitivity analyses explore the robustness of the base-case results by varying some key model 
parameters one at a time. For example, the risk of overall relapse during follow-up is varied between 
20% and 50%. The impact of different risks of dying because of toxicities following re-irradiation is 
explored using values from a systematic review [8]. We also examine the alternative that patients 
surviving the ‘potentially salvageable recurrence’ states have the same follow-up intervention (A or B) 
received in the ‘no evidence of disease’ state after primary treatment. 
Additionally, a two-way sensitivity analysis is performed to assess the simultaneous effect of varying the 
proportion of salvageable recurrences in the two arms, with all else unchanged in the model. This analysis 
is performed because of the uncertainty surrounding this parameter based on clinical opinion and not yet 
confirmed within the ongoing trial.  
Finally, a probabilistic sensitivity analysis is performed using Monte Carlo simulation with 5,000 random 
iterations from the distributions assigned to the model parameters. A beta distribution is chosen for 
probabilities and utilities, and a gamma distribution for costs (except for official tariffs, which are fixed 
in the model). A cost-effectiveness scatterplot illustrates the uncertainty surrounding the base-case ICUR, 
while cost-effectiveness acceptability curves (CEAC) quantify the probability of the intensive follow-up 
being cost-effective at different thresholds. 
The decision model is implemented in Microsoft Excel 2013 with the support of @RISK software 
(Palisade Corp) for the sensitivity analyses. 
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3. Results 
The baseline cost-effectiveness results yield an ICUR of €19,951 per QALY gained and an ICER of 
€13,123 per LYG (Table 7). In univariate sensitivity analysis (Table 8), the recurrence risk over the 5-
year follow-up is inversely proportional to the ICUR. Other variables including re-treatment-related 
mortality, cost of head and neck surgery and discounting have a limited effect on the results. In Figure 
2, the cost-effectiveness of the intensive follow-up (arm B) increases with the positive difference between 
the “curability” of arm B and arm A, reaching a maximum value of €6,330/QALY (€4,163/LYG) when 
this parameter is equal to 0.7 in arm B and 0.1 in arm A and a minimum value of €113,354/QALY 
(€74,561/LYG) when the difference between the two “curability” rates is only 0.05. 
In the cost-effectiveness plane (Figure 3), most ICURs (72%) are to the right of the €40,000 willingness-
to-pay for Italy; even considering the lowest threshold (i.e. €25,000), the maximal approach is cost-
effective in more than 50% of simulations. None of the simulations fell in the left side of the graph 
implying a negative difference in QALYs. In Figure 4, the CEAC shows that at a willingness-to-pay 
equal to zero almost 5% of the simulations report a cost-saving result. 
4. Discussion 
There is no agreement on a common follow-up strategy in HNC across clinical guidelines worldwide. 
Among them, the NCCN guidelines do not recommend routine imaging in the absence of symptoms [10], 
while clinical practice in Italy is heterogeneous and sometimes involves more intensive programs. The 
addition of routine MRI, CT and PET scans to the scheduled clinical examinations might increase the 
detection accuracy of recurrent HNC in patients, especially the asymptomatic ones. However, the 
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effectiveness (and cost-effectiveness) of more intensive follow-up schemes has never been shown with 
rigorous methods. 
The current model predicts costs and outcomes in terms of QALYs and survival gains of two alternative 
follow-up programs in HNC, corresponding to the arms of an ongoing clinical study. In this model, more 
intensive follow-up (maximal approach) appears cost-effective with a cost per QALY gained of €19,951, 
and more than two-thirds of the Monte Carlo simulations falling below the willingness-to-pay of €40,000. 
Moreover, the two-way sensitivity analysis shows that a difference in the proportion of potentially 
salvageable recurrence of about 0.15 between the two programs is sufficient to obtain an acceptable 
ICUR for arm B. The intermediate findings are comparable with data reported in the literature. For 
example, the 5-year survival is equal to 58% and 60.5% in arm A and arm B, respectively, which is 
consistent with the epidemiological data [2-4]. Moreover, the average stay of 13-14 months in the 
palliative treatment state is aligned with the median overall survival (i.e. 10 months) reported by 
Vermorken [9], since survival times are positively skewed.  
A recent study [22] systematically reviewed economic evaluations comparing alternative follow-up 
programs in cancer. Since no study considered HNC, and the incremental costs per QALY or LYG were 
rarely reported, comparisons with our results are not straightforward. However, we calculated an 
incremental cost per salvageable recurrence of €20,249, which coincides with the value reported (i.e. 
£18,077) by a modeling study comparing intensive versus standard surveillance for colorectal cancer in 
UK [23]. 
As a modeling study, the analysis inevitably represents a simplification of the real world. First, we 
assume that cancer-related deaths occur only during the active disease and patients without any cancer 
relapse experience the same risk of dying as the general population at the same age. However, previous 
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studies have reported an extra-mortality risk for HNC survivors [24], that may lead to lower ICER/ICUR 
if this information is incorporated into the model. Second, we do not consider second primary tumors not 
in the head and neck region and reported by previous studies [25-27] in the lung, esophagus, and colon. 
Third, the possibility of combined salvage treatment (e.g. surgery followed by re-irradiation) [28] and 
the use of radiotherapy with palliative intent [29] are disregarded, as well as any re-treatment failures 
other than death, such as non-fatal toxicities [8] or residual disease after salvage surgery. Fourth, this 
study does not account for patient’s anxiety and discomfort, nor for potential toxicities related to the use 
of PET and CT, and the risk of false-positive imaging leading to further costly investigations or 
unnecessary treatments [25, 30]. Fifth, the costs of follow-up are spread out over a 5-year period, thus 
the monthly cost represents an average value; however, we derive two different estimates for follow-up 
B, since most radiological assessments are performed during the first three years. Finally, the analysis is 
limited to direct healthcare costs, thus ignoring patient’s out-of-pocket costs and productivity losses due 
to frequent travels to the hospital; moreover, the cost of informal care may be substantial during the 
terminal disease stages, when 91% of patients are estimated to be cared for at home [31].  
This study is the first to investigate strategies of different intensity for monitoring patients after 
completion of treatments for primary HNC from a health economics perspective. Although a definite 
answer awaits the completion of the trial, the model shows that an intensive surveillance scheme may 
well be cost-effective in Italy. The trial protocol is currently under review, with a low-dose chest CT 
being included annually in heavy smokers according to the lung cancer screening NCCN guidelines [32]. 
Different results might be obtained by using alternative cost data, thus similar evaluations in other 
countries are valuable. Further research evaluating the benefits of a risk-adapted follow-up according to 
demographic, clinical or biomolecular factors is also warranted. 
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